MSD submits application to combine DPP-4 inhibitor and SGLT2 inhibitor for treatment type-2 diabetes
MSD President, Jannie Oosthuizen and Astellas Pharma President and CEO, Yoshihiko Hatanaka together announced that MSD has submitted an application for marketing approval of a…
Read More...
Read More...
